HK Stock Market Move | TYK MEDICINES-B (02410) surged over 9% in the afternoon as EGFR-TKI deuterated anlotinib was approved for first-line treatment of advanced non-small cell lung cancer.

TYK MEDICINES-B (02410) surged over 9% in the afternoon. As of the time of writing, it has risen 8.80%, priced at HKD 6.06, with a transaction value of HKD 15.1229 million. In recent news, Suzhou Kinlon Pharmaceutical has announced that its self-developed new generation EGFR-TKI innovative drug, Dacomitinib Mesylate Tablets (TY-9591, Kadaza), has officially obtained conditional approval for market launch from China's National Medical Products Administration. The indication is for first-line treatment in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases. Publicly available information shows that on July 21, 2026, Suzhou Kinlon Pharmaceutical established a strategic partnership with Qilu Pharmaceutical, granting Qilu commercialization rights for Dacomitinib in China. Suzhou Kinlon expects to receive a cash upfront payment of RMB 700 million and share subscription funds, as well as up to RMB 2.06 billion in milestone payments upon registration.